UKCA Marking and Great Britain Market Access: A Post-Brexit Guide

Since Brexit, Great Britain (England, Wales, and Scotland) is a distinct regulatory market from the European Union. Medical devices placed on the GB market are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) under the UK Medical Devices Regulations 2002 (as amended), not the EU MDR or IVDR. To reach GB today you generally need three things: a valid route to market (UKCA marking, or a CE mark accepted under the MHRA transition arrangements), registration of the device with the MHRA, and, if you are based outside the UK, a UK Responsible Person. The details and, above all, the deadlines have moved several times, so always confirm the current position on the MHRA website before you plan a submission.

Great Britain and Northern Ireland Are Not the Same Market

The single most common mistake is treating "the UK" as one regulatory territory. It is not. Great Britain follows the UK Medical Devices Regulations under MHRA oversight and uses UKCA marking. Northern Ireland, under the Windsor Framework (which replaced the Northern Ireland Protocol), continues to follow EU rules, so devices there carry the CE mark, with UKNI marking added only where a UK Approved Body performed the conformity assessment. A device strategy that ignores this split will either overspend on duplicate approvals or fail to gain lawful access in one of the two territories.

CE Marking Acceptance in GB Is a Moving Target

The MHRA did not impose a hard cliff edge for CE-marked devices. Instead it has repeatedly extended the acceptance of CE-marked devices on the GB market for defined transition periods, with the end dates tied to whether the device was certified under the older EU Directives or the newer EU MDR and IVDR. These windows have been revised more than once. The practical takeaway is simple: do not treat any single date you read in an older article as permanent. Check the current MHRA transition timelines before you decide whether you can rely on your CE mark for GB or need to pursue UKCA marking now.

UKCA Marking and UK Approved Bodies

UKCA (UK Conformity Assessed) marking is the GB equivalent of CE marking. For most non-lowest-risk devices, demonstrating conformity requires a UK Approved Body, the GB counterpart to an EU Notified Body. Approved Bodies are designated by the MHRA, and capacity has historically been limited, which is a real scheduling constraint. Self-certification without an Approved Body is only available for the lowest-risk classes. When you plan UKCA conformity assessment, factor in Approved Body availability and lead times, and confirm that your chosen body is designated for your specific device type.

MHRA Registration Is Mandatory

Regardless of which mark your device carries, it must be registered with the MHRA before being placed on the GB market. Registration is a separate obligation from conformity assessment, and it applies across risk classes on staggered grace periods that depend on device type. Key points to plan for:

• Device registration. The manufacturer or the UK Responsible Person registers the device with the MHRA before placement on the GB market.
• UKRP linkage. A non-UK manufacturer registers through its appointed UK Responsible Person, whose details form part of the registration.
• Keep it current. Registrations must be maintained and updated when device details, classification, or the responsible party change.

Non-UK Manufacturers Need a UK Responsible Person

If your business is not established in the UK, you must appoint a UK Responsible Person (UKRP) before placing a device on the GB market. The UKRP is analogous to the EU Authorised Representative and acts as your point of accountability with the MHRA. Responsibilities typically include handling registration, keeping technical documentation available to the MHRA on request, cooperating on vigilance and corrective actions, and forwarding complaints and incident information. Choose a UKRP with genuine regulatory competence and a clear written mandate, because a weak or purely administrative arrangement becomes a liability during an incident or an MHRA query.

The Future UK Regime and Post-Market Surveillance

The MHRA has been building out a strengthened, future UK medical devices regime through a phased program of new regulations rather than a single overnight replacement. Post-market surveillance has been an early priority, with enhanced requirements covering incident reporting, trend reporting, and periodic safety reporting, alongside signalled changes to international reliance routes and classification. Because this framework is arriving in stages, treat it as an active program to monitor, not a finished rulebook. Confirm which requirements are already in force and which are still on the roadmap before you commit to a compliance plan.

How Sequence Group Can Help

Sequence Group helps device manufacturers build a defensible Great Britain strategy that reflects the current MHRA position rather than outdated deadlines. We map your portfolio against GB and Northern Ireland requirements, advise on UKCA versus continued CE reliance, coordinate UK Approved Body engagement, manage MHRA registration, and support UK Responsible Person arrangements and post-market surveillance readiness. If you are planning GB access or reassessing a strategy built on an expired timeline, we can help you confirm what applies today and act on it with confidence.